Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,225 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03271047 | Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation | completed | Phase 2 | 75 | PfizerINDUSTRY | 5 | Jan 4, 2022 | clinicaltrials |
| NCT03824080 | Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes | completed | Phase 2 | 45 | GWT-TUD GmbHOTHER | 3 | Dec 21, 2021 | clinicaltrials |
| NCT02366195 | Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma(TVEC-325) | completed | Phase 2 | 112 | AmgenINDUSTRY | 13 | Nov 30, 2021 | clinicaltrials |
| NCT02725268 | A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer | completed | Phase 2 | 241 | Millennium Pharmaceuticals, Inc.INDUSTRY | 10 | Nov 24, 2021 | clinicaltrials |
| NCT00865969 | Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma(PTCL) | completed | Phase 2 | 129 | Spectrum Pharmaceuticals, IncINDUSTRY | 17 | Oct 29, 2021 | clinicaltrials |
| NCT01750918 | BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 166 | Novartis PharmaceuticalsINDUSTRY | 8 | Oct 29, 2021 | clinicaltrials |
| NCT01951586 | Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 226 | AmgenINDUSTRY | 10 | Oct 25, 2021 | clinicaltrials |
| NCT02038933 | Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) | completed | Phase 2 | 121 | Bristol-Myers SquibbINDUSTRY | 12 | Oct 14, 2021 | clinicaltrials |
| NCT02614833 | IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma | completed | Phase 2 | 242 | Immutep S.A.S.INDUSTRY | 7 | Oct 5, 2021 | clinicaltrials |
| NCT04379362 | MRI-guided Focal Laser Ablation(Unicorn) | unknown | Phase 2 | 53 | Radboud University Medical CenterOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02574377 | myDC/pDC in Stage III Melanoma Patients | completed | Phase 1 / Phase 2 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT02808247 | Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma(ANITA) | terminated | Phase 2 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 20, 2021 | clinicaltrials |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 23 | SanofiINDUSTRY | 5 | Sep 8, 2021 | clinicaltrials |
| NCT02471716 | Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor(FPA008-002) | completed | Phase 1 / Phase 2 | 66 | Five Prime Therapeutics, Inc.INDUSTRY | 6 | Aug 31, 2021 | clinicaltrials |
| NCT02045017 | Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency | completed | Phase 2 | 81 | CelgeneINDUSTRY | 8 | Aug 27, 2021 | clinicaltrials |
| NCT03050866 | Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)(CABA-V7) | unknown | Phase 2 | 140 | Erasmus Medical CenterOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT03263039 | Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab(RESPONDER) | unknown | Phase 2 | 80 | Erasmus Medical CenterOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT00041639 | Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer | completed | Phase 1 / Phase 2 | 75 | Gilead SciencesINDUSTRY | 4 | Aug 19, 2021 | clinicaltrials |
| NCT04998474 | FRAME-001 Personalized Vaccine in NSCLC | unknown | Phase 2 | 15 | Frame Pharmaceuticals B.V.INDUSTRY | 1 | Aug 10, 2021 | clinicaltrials |
| NCT02106312 | Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas(DOREMY) | unknown | Phase 2 | 80 | The Netherlands Cancer InstituteOTHER | 5 | Aug 4, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT01719380 | Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | completed | Phase 2 | 156 | PfizerINDUSTRY | 12 | Jun 23, 2021 | clinicaltrials |
| NCT01823835 | A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 152 | Genentech, Inc.INDUSTRY | 4 | Jun 18, 2021 | clinicaltrials |
| NCT03361969 | Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist. | completed | Phase 2 | 63 | Pantarhei Oncology B.V.OTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT02458638 | A Study of Atezolizumab in Advanced Solid Tumors | completed | Phase 2 | 474 | Hoffmann-La RocheINDUSTRY | 18 | Jun 4, 2021 | clinicaltrials |
| NCT02118337 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 97 | MedImmune LLCINDUSTRY | 6 | Jun 1, 2021 | clinicaltrials |
| NCT02574637 | Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease | terminated | Phase 2 | 29 | AstraZenecaINDUSTRY | 12 | May 26, 2021 | clinicaltrials |
| NCT03411161 | S 81694 Plus Paclitaxel in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Institut de Recherches Internationales ServierOTHER | 4 | May 25, 2021 | clinicaltrials |
| NCT00290667 | Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma | completed | Phase 2 | 586 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 9 | May 18, 2021 | clinicaltrials |
| NCT03134846 | Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate(ICON) | unknown | Phase 1 / Phase 2 | 79 | University Medical Center GroningenOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT01046006 | Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia | completed | Phase 2 | 59 | Meletios A. DimopoulosOTHER | 3 | Apr 30, 2021 | clinicaltrials |
| NCT03620292 | Fluorescence Image Guided Surgery in Cholangiocarcinoma(COUGAR) | unknown | Phase 1 / Phase 2 | 12 | University Medical Center GroningenOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT01844765 | Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.(DIALOG) | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 13 | Apr 22, 2021 | clinicaltrials |
| NCT01077986 | Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 35 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT01077999 | Chemoradiation and Panitumumab for Esophageal Cancer | completed | Phase 2 | 78 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT01210911 | Metformin Combined With Chemotherapy for Pancreatic Cancer(GEM) | completed | Phase 2 | 120 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02695459 | Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin | unknown | Phase 2 | 39 | The Netherlands Cancer InstituteOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT03025893 | A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme(STELLAR) | unknown | Phase 2 / Phase 3 | 100 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03313323 | Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma(Zirconipi) | unknown | Phase 2 | 29 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT04126876 | A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma(INTRIM) | recruiting | Phase 2 | 214 | A.J.M. van den EertweghOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT02117466 | Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer(IMPACT-CRC) | terminated | Phase 1 / Phase 2 | 85 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT04838496 | Induction Chemotherapy for Locally Advanced Rectal Cancer(MEND-IT) | unknown | Phase 2 | 128 | Catharina Ziekenhuis EindhovenOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT01610336 | A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | completed | Phase 2 | 161 | Novartis PharmaceuticalsINDUSTRY | 14 | Apr 8, 2021 | clinicaltrials |
| NCT01563354 | 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial(LUNA) | completed | Phase 2 | 124 | Novartis PharmaceuticalsINDUSTRY | 9 | Apr 2, 2021 | clinicaltrials |
| NCT02025218 | Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients(IRENE) | terminated | Phase 2 | 21 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT02528682 | MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT(PSCT19) | completed | Phase 1 / Phase 2 | 10 | Radboud University Medical CenterOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03951415 | Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer(DOMEC) | unknown | Phase 2 | 55 | Leiden University Medical CenterOTHER | 1 | Apr 1, 2021 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials